Artesunate ameliorates leflunomide low-response against bone destruction in rheumatoid arthritis via cGMP-PKG signalling
- 17 December 2025
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 150, 157713
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82274177)
- National Natural Science Foundation of China (82174042)
- National Natural Science Foundation of China (82574664)
- Fundo para o Desenvolvimento das Ciências e da Tecnologia (002/2023/ALC)
- China Academy of Chinese Medical Sciences (CI2024E003)
This publication has 27 references indexed in Scilit:
- Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021The Lancet Rheumatology, 2023
- Artesunate attenuates bone erosion in rheumatoid arthritis by suppressing reactive oxygen species via activating p62/Nrf2 signalingBiomedicine & Pharmacotherapy, 2021
- The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT StudyDrugs in R&D, 2019
- Use of artesunate in non-malarial indicationsMedecine Et Maladies Infectieuses, 2018
- Artesunate attenuates ACLT-induced osteoarthritis by suppressing osteoclastogenesis and aberrant angiogenesisBiomedicine & Pharmacotherapy, 2017
- From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapySeminars in Cancer Biology, 2017
- Rheumatoid arthritisThe Lancet, 2016
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2015
- Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritisPharmacological Reports, 2015
- The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF‐κB ligand–stimulated induction of nuclear factor of activated T cells c1Arthritis & Rheumatism, 2004